CLLS

Cellectis

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

France

Next Earnings Date

11

Business Summary

Cellectis is a clinical-stage biopharmaceutical company focused on developing immunotherapies to target and eradicate cancer. The company utilizes its gene-editing technologies to engineer allogeneic CAR T-cells, creating off-the-shelf cancer treatments.

 


Analyze CLLS on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$379

Forward P/E

-

PEG

-

PRICE TO SALES

5.2

PRICE TO BOOK

3.9

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.33

Next Year EPS Growth Estimate

-$0.62

Next Year Revenue Growth Estimate

-12.90%

Return on Equity (ROE)

-35.20%

FREE CASH FLOW

Operating Margin

-35.10%

Debt-to-Equity

0.9

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze CLLS on TradingView

Gainseekers Quantitative Analysis

Summary

Cellectis is an unprofitable biotechnology firm with a negative EPS of -$0.33 and a Return on Equity of -35.20%. The company has a Price to Sales ratio of 5.2 and a Debt to Equity ratio of 0.9. Projections indicate a future sales decline of -12.90% and a worsening EPS of -$0.62 for the next year.

AI Exposure / Tech Reliance

The provided data does not contain any metrics related to AI exposure or specific technological reliance.

The Bull Case

The bull case is supported by a strong analyst Consensus Rating of 1.57 and a Mean Consensus Target Price of $7.67. A low Short % of Float at 0.80% also indicates limited bearish bets against the stock.

The Bear Case

The bear case centers on the company's unprofitability, evidenced by a -35.10% Operating Margin and a -35.20% Return on Equity. This is compounded by a projected -12.90% decline in sales growth for the next year.

Market Sentiment & Smart Money

Short Interest %

0.80%

Analyst Consensus

1.57

Average Analyst Price Target

$7.67

Institutional Ownership %

17.00%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.